CBAY

Cymabay Therapeutics

Delisted

CBAY was delisted on the 21st of March, 2024.

100 hedge funds and large institutions have $218M invested in Cymabay Therapeutics in 2022 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 18 increasing their positions, 30 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

more call options, than puts

Call options by funds: $ | Put options by funds: $

more capital invested

Capital invested by funds: $ → $

more funds holding in top 10

Funds holding in top 10:

less funds holding

Funds holding:

33% less first-time investments, than exits

New positions opened: 12 | Existing positions closed: 18

40% less repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 30

Holders
100
Holders Change
Holders Change %
% of All Funds
Holding in Top 10
6
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
Increased
Reduced
Closed
Calls
$865K
Puts
$520K
Net Calls
Net Calls Change

Top Buyers

1 +$2.8M
2 +$2.09M
3 +$1.19M
4
Two Sigma Advisers
Two Sigma Advisers
New York
+$813K
5
Walleye Capital
Walleye Capital
New York
+$770K

Top Sellers

1 -$5.19M
2 -$1.03M
3 -$923K
4
Morgan Stanley
Morgan Stanley
New York
-$861K
5
PCM
Pinz Capital Management
New York
-$683K
Name Holding Trade Value Shares
Change
Change in
Stake
51
$350K
52
$347K
53
$335K
54
$255K
55
$210K
56
$208K
57
$206K
58
$185K
59
$183K
60
$140K
61
$121K
62
$106K
63
$101K
64
$93K
65
$88K
66
$87K
67
$81K
68
$66K
69
$65K
70
$64K
71
$63K
72
$61K
73
$55K
74
$50K
75
$45K